Update on Apealea, Potential Ovarian Cancer Therapy, Set for ASCO 2018 in June

Update on Apealea, Potential Ovarian Cancer Therapy, Set for ASCO 2018 in June
Apealea, a water-soluble formulation of the chemotherapy paclitaxel, is not inferior to the standard formulation, Taxol (cremophor- EL paclitaxel), and may even improve the survival of ovarian cancer patients who responded to platinum-based chemotherapy, updated Phase 3 trial data suggests. The data will be presented June 4 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *